

R⁶ is methyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, or C₃₋₆-cycloalkyl,

R⁷ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C₃₋₆-cycloalkyl, or C₂₋₄-acyl, or

R⁶ and R⁷ together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or R⁶ and R⁷ together with the nitrogen between them form phthalimido;

R³ is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C₁₋₆-alkoxy, -CF₃, or -OCF₃;

R⁴ is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

R⁵ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C₁₋₆-alkoxy, halogen, -CF₃, or -OCF₃;

or a pharmaceutically acceptable salt thereof.--

--29. (Amended) A compound selected from the group consisting of:

- (a) 2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
- (b) 2-(2-methyl-3-phthalimidophenylimino)imidazolidine,
- (c) 2-(3-acetylamino-6-chlorophenylimino)imidazolidine,
- (d) 2-(3-amino-2-methylphenylimino)imidazolidine,

*ED
OCT 17*

- (e) 2-(3-amino-4,6-dibromo-2-methylphenylimino)imidazolidine,
- (f) 2-(3-amino-4-methylphenylimino)imidazolidine,
- (g) 2-(4,6-dibromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
- (h) 2-(4-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
- (i) 2-(6-chloro-3-dimethylamino-2-methylphenylimino)imidazolidine, and
- (j) 2-(6-chloro-3-phthalimidophenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof.--

--34. (Amended) A pharmaceutical composition comprising:

(a) a compound selected from the group consisting of:

2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(5-amino-2-chloro-4-dimethylamino-2-methylphenylimino)imidazolidine, and

2-(3-amino-2-methylphenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof, and

(b) one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.-

13

--35. (Amended) A pharmaceutical composition comprising 2-(3-dimethylamino-2-methylphenylimino)imidazolidine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.--

--38. (Amended) A pharmaceutical composition comprising:

(a) a compound selected from the group consisting of:

2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(2-methyl-3-phthalimidophenylimino)imidazolidine,

2-(3-acetylamino-6-chlorophenylimino)imidazolidine,

2-(3-amino-2-methylphenylimino)imidazolidine,

2-(3-amino-4,6-dibromo-2-methylphenylimino)imidazolidine,

2-(3-amino-4-methylphenylimino)imidazolidine,

2-(4,6-dibromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(4-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,


2-(6-chloro-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-chloro-3-phthalimidophenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof; and

(b) one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.-

--39. (Twice amended) A pharmaceutical composition comprising a compound of the formula (II)



wherein:

R^1 is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C_{3-6} -cycloalkyl, C_{1-6} -alkoxy, halogen, $-CF_3$, or $-OCF_3$;

R^2 is $-NR^6R^7$, wherein

R^6 is ethyl,

R^7 is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C_{3-6} -cycloalkyl, or C_{2-4} -acyl, or

R^6 and R^7 together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or R^6 and R^7 together with the nitrogen between them form phthalimido;

R^3 is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C_{1-6} -alkoxy, $-CF_3$, or $-OCF_3$;


R^4 is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

R^5 is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C_{1-6} -alkoxy, halogen, $-CF_3$, or $-OCF_3$;

or a pharmaceutically acceptable salt thereof; and

Copy
one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.--

--51. (Amended) A compound of the formula (II)



wherein:

R¹ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, halogen, -CF₃, or -OCF₃;

R² is -NR⁶R⁷, wherein R⁶ and R⁷ together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or R⁶ and R⁷ together with the nitrogen between them form phthalimido;


R³ is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C₁₋₆-alkoxy, -CF₃, or -OCF₃;

R⁴ is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

R⁵ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C₁₋₆-alkoxy, halogen, -CF₃, or -OCF₃;

or a pharmaceutically acceptable salt thereof.--

--52. (Amended) A compound of the formula (II)



wherein:

R¹ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, cyclopropyl, C₁₋₄-alkoxy, halogen, -CF₃, or -OCF₃;

R² is -NR⁶R⁷, wherein R⁶ and R⁷ together with the nitrogen between them form phthalimido;


R³ is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, C₁₋₄-alkoxy, -CF₃, or -OCF₃;

R⁴ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, or halogen; and,

R⁵ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, C₁₋₄-alkoxy, halogen, -CF₃, or -OCF₃;

or a pharmaceutically acceptable salt thereof.--

--53. (Amended) A compound of the formula (II)



wherein:

R¹ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, cyclopropyl, C₁₋₃-alkoxy, halogen, or -CF₃;

R² is -NR⁶R⁷, wherein R⁶ and R⁷ together with the nitrogen between them form phthalimido;

B
Amphy


R³ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, C₁₋₃-alkoxy, halogen, or -CF₃;

R⁴ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or halogen; and,

R⁵ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, C₁₋₃-alkoxy, halogen, or -CF₃;

or a pharmaceutically acceptable salt thereof.--

--54. (Amended) A compound of the formula (II)



wherein:

R¹ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, or halogen;

R² is -NR⁶R⁷, wherein R⁶ and R⁷ together with the nitrogen between them form phthalimido;

R³ is hydrogen, methyl, fluorine, chlorine, or bromine;

R⁴ is hydrogen; and

R⁵ is hydrogen, methyl, chlorine, or bromine;

or a pharmaceutically acceptable salt thereof.--

Please add new claim 70 as follows.

W

--70. (new) 2-(3-dimethylamino-2-methylphenylimino)imidazolidine, or a pharmaceutically acceptable salt thereof.--